![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bayer Ord | LSE:BYR | London | Ordinary Share | DE000BAY0017 | REG SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.93 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:3741K Bayer AG 25 April 2003 Bayer: First-quarter sales improve by more than 4 percent - Operating result also up year on year Double-digit growth in operating result, predicted for 2003 / Lipobay/Baycol: more settlement agreements concluded in U.S. Leverkusen - According to preliminary figures, the Bayer Group recorded sales of EUR. 7.3 billion from continuing operations in the first quarter of 2003. As the company announced prior to the Annual Stockholders' Meeting on Friday in Cologne, this represents a year-on-year increase of more than 4 percent after translation and an improvement of over 15 percent in local currencies. Provisional first-quarter data so far available indicate that the operating result also exceeded the figure for the same period of 2002, which was EUR 840 million. The Bayer Group expects to increase its operating result from continuing operations by a double-digit percentage in 2003, provided current economic conditions do not seriously worsen. At the Annual Stockholders' Meeting, Bayer also presented updated figures concerning lawsuits pending in the United States in connection with the drug product Lipobay/Baycol, which was voluntarily withdrawn from the market in the summer of 2001. Without concession of liability, Bayer so far has entered settlement agreements with 740 individuals, which will result in total payments of approximately 219 million U.S. dollars. Some 8,600 suits have now been filed in the United States. Note to editors: The interim report for the first quarter of 2003 will be published on May 7, 2003 in the Stockholders' Newsletter. Bayer AG, Investor Relations contacts: Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Judith Nestmann (+49-214-30-66836) Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S.Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward- looking statement or to conform them to future events or developments. This information is provided by RNS The company news service from the London Stock Exchange END TSTDELBLXZBFBBD
1 Year Bayer Ord Chart |
1 Month Bayer Ord Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions